title: [Immunization against Trypanosoma cruzi and tumor growth in mice].
abstract: The evidence has been produced that immunological mechanisms are involved in the known anticancer phenomenon of T. cruzi. Non-inbred albino mice were immunized with avirulent cultures of three strains and seven clones and then transplanted a tumor--sarcoma-180 or Ehrlich's adenocarcinoma. The used cultures induced the generation of T. cruzi antibodies whose level peaked by postimmunization days 50-60: the titers being 1:40-1:80 and the spread among the mice being 60%. Concurrently, immunization against T. cruzi provided a certain oncoprotective effect. In the immunized mice, the sizes of sarcoma-180 and adenocarcinoma were 1.5-2.0 and 2.0-2.5 times, respectively, less than those in the non-immunized ones. The antitumor protection was directly related to the murine blood T. cruzi antibody level during which implantation of a tumor occurred. At the peak of an immune response, the effect was 2 times higher than that in the early postimmunization periods. T. cruzi strains that were more immunogenic than clones ensured a more significant oncoprotection. The latter was more considerable in mice having antibody titers of 1:40-1:80 than in those with antibody titers of 1:10-1:20 and particularly in the animals showing no humoral response to the administration of the parasites at all.
authors.forename: V D
authors.initials: VD
authors.lastname: Kallinikova
authors.forename: E N
authors.initials: EN
authors.lastname: Borisova
authors.forename: L V
authors.initials: LV
authors.lastname: Pakhorukova
authors.forename: T A
authors.initials: TA
authors.lastname: Ogloblina
authors.forename: Ts
authors.initials: Ts
authors.lastname: Batmonkh
authors.forename: E G
authors.initials: EG
authors.lastname: Kravtsov
authors.forename: L P
authors.initials: LP
authors.lastname: Karpenko
authors.forename: M V
authors.initials: MV
authors.lastname: Dalin
mesh_terms: D000230:Adenocarcinoma / Q000517:prevention & control*; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D014355:Chagas Disease / Q000276:immunology*; D007114:Immunization; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D016052:Protozoan Vaccines / Q000008:administration & dosage*; D012513:Sarcoma, Experimental / Q000517:prevention & control*; D012878:Skin Neoplasms / Q000517:prevention & control*; D013045:Species Specificity; D013997:Time Factors; D014349:Trypanosoma cruzi / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage
chemical_list: D000913:Antibodies, Protozoan; D016052:Protozoan Vaccines; D014613:Vaccines, Attenuated